The current financial score of Rezolute Inc is 5.45. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Rezolute Inc is 6.23. Its current P/E ratio is -4.84, which is -86.14% below the recent high of -0.67 and -141.97% above the recent low of -11.71.
The current earnings forecast score of Rezolute Inc is 8.40. The average price target is 7.67, with a high of 14.00 and a low of 4.00.
The current price momentum score of Rezolute Inc is 4.96. Currently, the stock price is trading between the resistance level at 4.79 and the support level at 3.38, making it suitable for range-bound swing trading.
The current institutional shareholding score of Rezolute Inc is 10.00. The latest institutional shareholding proportion is 105.15%, representing a quarter-over-quarter decrease of 4.87%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
No risk assessment score is currently available for Rezolute Inc. The Biotechnology & Medical Research industry's average is 3.92. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.